UPSTREAM results #OP0223 suggest that the newly developed and preliminary validated MSKUS PsA dz activity and damage scores could be used in observational and controlled trials. #EULAR2021 @RheumNow https://t.co/Tw7OWyMcgX https://t.co/WiT0yGwVqK

• http://ow.ly/dBaI50F2i4y

Does Guselkumab (IL23-i) modulate gene expression in #PsA? Dr Siebert analysed samples from DISCOVER RCTs & reported normalisation of⬆️regulated genes (e.g. Neutrophil,monocyte) and ⬇️regulated (B-,T- and NK cells) signatures by GUS post-therapy #EULAR2021 #POS0195 @RheumNow https://t.co/2qtpxrrwkF

I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus ⭐️⬇️AS activity w/ or w/o MRI sacroilitis Abs#OP0142 #EULAR2021 @RheumNow

GUS causes ⬇️ in serum collagen C1M (marker of joint response), C3M, C4M, C6M. Pts achieving ACR20 at week 24 had greater C1M reduction than non-responder. Abstract #POS1036 #EULAR2021 @RheumNow https://t.co/4JqbaMexuR https://t.co/gXltKn6qIc

• http://ow.ly/D1V050F2D5E

In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u

• https://ard.bmj.com/content/80/Suppl_1/783

#EULAR2021 PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate ) Dr. Rachel Tate reviews two abstracts - OP0051 and OP0049 - presented at the virtual EULAR 2021 meeting. https://t.co/sUXTXDXrFh https://t.co/tQZktnlUXj

• https://bit.ly/3wSTLSo

#POS0196 1 year results of the SELECT-PsA 2 study: Inadequate responders to ≥1bDMARD subjected to #upadacitinib maintained efficacy throughout week 56 (74% of pts completed 1-year) #EULAR2021 @RheumNow https://t.co/xpqhzgeI6q